Ligelizumab Completed Phase 2 Trials for Atopic Dermatitis (AD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01552629A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients